E. David Crawford, MD of University of Colorado, Denver in Aurora, Colorado discusses “The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration Resistant Prostate Cancer.” Keywords: castration resistant prostate cancer, therapeutic layering, therapeutic agents, RADAR...Read More
E. David Crawford, MD
University of Colorado, Denver
E. David Crawford is Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver (UCD) in Denver, Colorado. He is also the E. David Crawford Endowed Chair in Urologic Oncology at UCD.
Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in Urology at the Good Samaritan Hospital in Cincinnati. He was subsequently awarded a Genitourinary Cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles.
Dr. Crawford is a nationally recognized expert in prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored more than 400 articles, which have been published in such journals as Urology, The New England Journal of Medicine, and the Journal of the National Cancer Institute. He has published five textbooks. He is also an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology. He serves as Medical Editor of Grand Rounds in Urology.
Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical AUA, he is a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and he chairs the national Prostate Conditions Education Council (PCEC).
Articles by E. David Crawford, MD
Posted by E. David Crawford, MD | Nov 2017
Agenda Faculty Supporters Ask a Question Agenda Friday, November 10, 2017 7:00 AM – 8:00 AM Registration – Arizona II & III Foyer Industry Breakfast Symposium – Arizona II & III PROST8™ FOR PRIMARY CARE – Moderator – David Crawford, MD 8:00 – 8:10 AM Welcome and Introduction E. David Crawford, MD 8:10 – 8:30 AM Prostate Physiology: The Most Diseased Organ in the Male Body View Presentation Ryan P. Terlecki, MD, FACS 8:30 – 8:50 AM How to Differentiate the Causes of Lower Urinary Tract Symptoms View Presentation Matt T. Rosenberg, MD 8:50 – 9:10 AM Association of BPH with OAB View Presentation Ryan P. Terlecki, MD, FACS 9:10 – 9:30 AM Prostate Cancer: Why The Controversy? View Presentation Michael S Cookson, MD, MMHC 9:30 – 9:50 AM Break and Visit Exhibits – Maricopa II & III 9:50 – 10:10 AM Biomarkers: A Way Forward with Prostate Cancer Early Detection View Presentation E. David Crawford, MD 10:10 – 10:30 AM Prostate Cancer: Identifying the Toothless Lions View Presentation E. David Crawford, MD 10:30 – 10:50 AM Testosterone, the FDA, and CVD Risk Controversies View Presentation Matt T. Rosenberg, MD 10:50 – 11:10 AM The Role of Shared Decision-making in Prostate Care View Presentation Matt T. Rosenberg, MD 11:10 – 11:45 AM Panel Discussion 12:00 – 1:00 PM Industry Lunch Symposium – Maricopa I Elevate Care in Advanced Prostate Cancer Jonathan L. Silberstein,...Read More
Posted by E. David Crawford, MD | Jun 2017
Release date: May 25, 2017 Expiration date: May 25, 2018 Start Activity Program OverviewFaculty Program Overview Prostate cancer (PCa) is associated with the second highest number of cancer related deaths in men, second only to skin cancer. It is the most commonly diagnosed problem with the genitourinary tract and approximately one in six men will be diagnosed with PCa in his lifetime. According to the American Cancer Society, it is estimated that there will be 180,890 new cases of prostate cancer, and about 26,120 deaths from prostate cancer in 2016. A major debate in the use of ADT is...Read More
Posted by E. David Crawford, MD | May 2017
These downloadable slides by Dr. E. David Crawford, MD are on the topic of current ADT challenges and an overview of the effects commonly experienced by men being treated with androgen deprivation therapy. These slides were presented at a satellite symposium presented in conjunction with the AUA Annual Meeting held on Sunday, May 14, 2017 entitled “Navigating the Adverse Effects of ADT: Improving Patient Outcomes”. Download...Read More
Navigating the Adverse Effects of ADT: Improving Patient Outcomes – Slide Deck from 2017 AUA Symposium
Posted by E. David Crawford, MD | May 2017
These are downloadable slide decks from the symposium “Navigating the Adverse Effects of ADT: Improving Patient Outcomes” presented in conjunction with the AUA Annual Meeting on May 14, 2017. This program emphasizes the importance of considering adverse effects of ADT treatment in patients with prostate cancer including hot flashes, bone adverse effects, ADT mechanisms of action, cardiovascular health, and current challenges. Download Slides Download Slides Download Slides Download...Read More